222 results about "Chronic liver disease" patented technology

The invention relates generally to compositions comprising antioxidants useful for reducing oxidative stress and lipid peroxidation, and treating chronic liver disease, chronic hepatitis C virus infection and non-alcoholic steatohepatitis. In particular, the invention relates to the preparation and oral administration of compositions comprising glycyrrhizin, schisandra, ascorbic acid, L-glutathione, silymarin, lipoic acid, and d-alpha-tocopherol. The invention also relates to the preparation and parenteral administration of compositions comprising glycyrrhizin, ascorbic acid, L-glutathione, and vitamin B-complex, preferably by infusion or intravenous injection. The invention further relates to methods of using the antioxidants, oral compositions and parenteral compositions.

Certain biomarkers and biomarker combinations are useful in a qualifying hepatocellular carcinoma status in a patient. A diagnostic methodology employing these biomarkers and combinations can distinguish between hepatocellular carcinoma and chronic liver disease, for example.

Hepatitis C virus (HCV) is a major cause of chronic liver disease and affects over 270 million individuals worldwide. The HCV genome is a single-stranded RNA that functions as both a messenger RNA and replication template, making it an attractive target for the study of RNA interference. Double-stranded short interfering RNA (siRNA) molecules designed to target the HCV genome are disclosed herein.

A compound preparation consists of ornithine or its salt and asparagic acid or its salt as well as proper amount of supplementary material; and is prepared into oral preparation or injection through mechanical mixing and other process. The said compound preparation is used for treating various acute hepatitis, chronic hepatosis and hepatic encephacopathy and has the obvious effects of protecting liver and strengthening physique. The preparation process is simple, short in production period and low in cost.

The present embodiments relate to methods for the prevention and treatment of inflammatory conditions such as alcoholic liver disease (ALD). More specifically the present embodiments relate to the prevention and treatment of ALD through the administration of an Retinoic Acid Receptor (RAR) agonist. Some embodiments relate to use of tazarotene in the prevention and treatment of alcohol-induced liver injury, alcohol-related liver disease, fatty liver disease, hepatic steatosis, alcoholic hepatitis or alcoholic cirrhosis.

The present invention is concerned with deuterium-enriched pyrimidine compounds of formula I, their derivatives, enantiomers, diastereomers, solvates and pharmaceutical salts thereof,and their uses in the treatment, prevention and modulation of various diseases including chronic liver diseases, liver cirrhosis, liver fibrosis, hepatocellular carcinoma, liver cancer, renal cell carcinoma, kidney cancer, colorectal cancer, brain cancer, breast cancer, blood cancer, lung cancer, thyroid cancer, ovarian cancer, pancreas cancer, prostate cancer, stomach cancer, testicular cancer, uterus cancer, intestinal cancer, skin cancer, and other forms of cancer, carcinoid tumors, teratocarcinoma, tumor progression, metastasis and fibrosis in the neuroendocrine neoplasia, fibrotic processes as well as a disease state modulated directly or indirectly with 5-HT receptors, 5-HT1, 5-HT1A, 5-HT2 receptors, 5-HT2A and 5-HT2B receptors, dopamine receptors and multiple kinase pathways.

A Chinese medicine in the form of honeyed pills for treating chronic hepatism and hepatic fibrosis is prepared from 13 Chinese-medicinal materials including saffron, red sage root, astragalus root, Chinese angelica root, etc through cleaning, pulverizing, sieving, proportionally mixing, adding honey, pilling and Co-60 sterilizing. Its advantage is high curative effect up to 94%.

A Disease Severity Index (DSI) is provided for assessment of chronic liver disease in a patient using non-invasive liver function test results. A DSI was derived from non-invasive liver function test results based on hepatic blood flow. The DSI is used in methods for prediction of clinical outcomes, prediction of response to antiviral treatment, and assessment of progression of chronic liver diseases. Non-invasive methods to diagnose three distinct categories of patients with Primary Sclerosing Cholangitis (PSC) are provided. The methods can be used to diagnose PSC patients as Slow Progressors, Moderate Progressors and Rapid Progressors.

An anti-inflammatory and anti-fibrotic antioxidant formulation for treatment of hepatic oxidative stress and cirrhosis is disclosed. The antioxidant formulation can further include at least one of a hepatitis C virus-specific or a non-alcoholic steatohepatitis-specific formulation comprising one or more compounds to retard the progression of liver fibrosis and possibly reverse an established fibrosis. Methods of treatment or therapies for treating chronic liver disease and chronic hepatitis are also provided.

The invention belongs to the field of pharmaceutical chemical engineering, and discloses a L-ornithine lipoic acid compound salt, and a preparation method and application thereof. A structural formula of the L-ornithine lipoic acid compound salt is as shown in the formula I. The L-ornithine lipoic acid compound salt has functions of preventing and treating hepatic coma caused by acute and chronic hepatic diseases such as liver cirrhosis, fatty liver, hepatitis and the like and can be used for preparing a medicament for treating hepatic coma. The preparation method for the L-ornithine lipoic acid compound salt is simple and easy to operate and is low in cost; the product is high in purity.

An anti-inflammatory and anti-fibrotic antioxidant formulation for treatment of hepatic oxidative stress and cirrhosis is disclosed. The antioxidant formulation can further include at least one of a hepatitis C virus-specific or a non-alcoholic steatohepatitis-specific formulation comprising one or more compounds to retard the progression of liver fibrosis and possibly reverse an established fibrosis. Methods of treatment or therapies for treating chronic liver disease and chronic hepatitis are also provided.

The invention refers to a Tiopronin freeze-dried powder-form injection for treating chronic liver diseases. It comprises active Tiopronin compound 1-1000mg, like 50mg, 100mg or 200mg, and the receivable carrier of drug is selected from one or multiple of low-molecular dextran, mannite, cyclodextrin, soluble amylum, glucide, NaCl, benzoic acid, cellulose or water. It also refers to the making method including the steps of preparing medical liquid, eliminating heat source, sterilizing, canning and freeze-drying.

The invention discloses a FXR agonist and a preparation method and application thereof, and particularly relates to compounds with a structure shown in a formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof. The FXR agonist has the advantages that the series of compounds can be used for treating FXR-mediated diseases, such as cardiovascular disease, atherosclerosis, arteriosclerosis, hypercholesterolemia, hyperlipidemia chronic hepatitis disease, chronic liver disease, gastrointestinal disease, nephrosis, metabolic disease, cancers (such as colorectal cancer) and nerve signs (such as stroke); the broad medical application is realized, and a new generation of FXR regulator is expected to develop. The formula (I) is shown in the description.

Provided are a use and a method for treating chronic liver diseases such as liver fibrosis and liver cirrhosis by using hepatocyte nuclear factor 1a (HNF1a). Regulation of the expression of HNF1a gene can effectively induce the hepatocyte nuclear factor, thus providing a new means for treating chronic liver diseases.

The present invention relates to belongs to the field of Chinese medicine technology, relates to compound Chinese medicine preparation for treating chronic hepatosis, and is especially compound Chinese medicine preparation for treating hepatitis and hepatic fibrosis and its preparation process. The compound Chinese medicine preparation is prepared with red sage, fermented aweto powder, peach kernel, pine pollen, gynostemma pentaphylla, schisandra extract and medicinal supplementary material, and may be in different orally taken preparation forms. The compound Chinese medicine preparation has high effect of preventing and treating hepatic fibrosis and treating hepatitis and no obvious toxic side effect.

The invention relates to a traditional Chinese medicine composition for treating tuberculosis, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from the following raw material medicine: hoantchy root, rhizome polygonati, lily, dwarf lilyturf turber, radix stemonae, bletilla, peach kernel, salvia miltiorrhiza, donkey-hide gelatin, wild buckwheat root, bulbus fritilariae, trichosanthes bark, and radix glehniae. The medicine is generally suitable for tuberculosis patients, particularly suitable for patients suffering from combined chronic diseases such as tubercular meningitis, diabetes, chronic liver disease, chronic renal disease, and the like, fever, night sweat, and physical weakness.

A Disease Severity Index (DSI) is provided for assessment of chronic liver disease in a patient using non-invasive liver function test results. A DSI was derived from non-invasive liver function test results based on hepatic blood flow. The DSI is used in methods for prediction of clinical outcomes, prediction of response to antiviral treatment, and assessment of progression of chronic liver diseases. Non-invasive methods to diagnose three distinct categories of patients with Primary Sclerosing Cholangitis (PSC) are provided. The methods can be used to diagnose PSC patients as Slow Progressors, Moderate Progressors and Rapid Progressors.

The invention belongs to the field of biomedicines, and provides a scheme of combination of an apoptotic inhibitor and Farnesoid XReceptor (FXR) agonist for exerting the synergetic liver protection anti-fibrosis effect. Particularly, the invention relates to therapeutic medication measure for liver fibrosis at an important stage according to chronic liver disease. The invention provides application of combination of FXR agonist and the apoptotic inhibitor in preparation of superior anti-hepatic fibrosis drugs, and particularly the FXR agonist, namely obeticholic acid and the apoptotic inhibitor IDN6556 are selected for use, when the FXR agonist and the apoptotic inhibitor are subjected to low-dosage combination, the glutamic-pyruvic transaminase level in serum can be obviously reduced, thestructural forms and functions of liver cells can be improved, and the fibrotic symptoms is reduced, and due to drug combination, the liver protection effect is obviously superior to that of the single use of the FXR agonist and the apoptotic inhibitor. The invention provides a preparation method of a new superior liver protection anti-fibrosis drug.

The invention provides a method for establishment of a macaca mulatta liver fibrosis model by intraperitoneal injection. The method includes the steps of: selecting 5-9kg male macaca mulattas of 2-3 years old as the model animals, performing feeding with high-fat feed during modeling, supplying an alcohol water solution with a volume concentration of 9%-11% for drinking, and injecting CCl4 injection to each macaca mulatta during modeling twice a week by intraperitoneal injection continuously for 20-30 weeks, and controlling the injecting amount at 0.8-1.5mL / kg each time, thus achieving successful modeling. The animal model establishment method provided by the invention is simple, safe and reliable, has the characteristics of short modeling time, high success rate, good repeatability, goodanimal tolerance and low death rate, and can be used for studying the pathogenesis, pathogenic factors and treatment means of chronic liver diseases.

The present invention relates to a pharmaceutical composition comprising a combination of an FXR agonist and at least one lipid lowering agent (e.g., PPAR-alpha agonist, PPAR-delta agonist, PPAR-alpha and delta dual agonist, and / or statin). Also disclosed is use of the combination for the treatment or prevention of a FXR mediated disease or condition, such as primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), portal hypertension, bile acid diarrhea, NAFLD (nonalcoholic fatty liver disease), NASH (non-alcohol-induced steatohepatitis), and other chronic liver diseases. The combination of the present invention is useful for the treatment or prevention of conditions related to elevated lipid and liver enzyme levels. The present invention also relates to packs or kits including the pharmaceutical combination.

The invention discloses a compound composition of traditional Chinese medicine granules for regulating liver regeneration and prevention and treatment methods for chronic liver diseases by using the compound alone or in combination with antiviral medicine. The medicine is composed of: 5-30 parts of prepared Chinese foxglove root, 5-30 parts of virgate wormwood, 3-9 parts of turmeric, 3-12 parts of licorice, 3-15 parts of schisandra fruit, 5-15 parts of underleaf pearl, 5-30 parts of diffusa , 5-30 parts of poria, 5-30 parts of coix seed, 5-30 parts of salvia fruit, 1-10 parts of curcuma rhizome, 3-12 parts of dodder, and 5-15 parts of mistletoe For people suffering from chronic liver diseases (drug-induced liver disease, alcoholic or non-alcoholic fatty liver disease, autoimmune liver disease, viral hepatitis, etc.) which have high risk of liver failure, liver cirrhosis, and liver cancer, and people suffering from liver cancer or people after liver cancer surgery, clinical and experimental evidences show that the traditional Chinese medicine granules have synergies of regulation of liver regeneration and anti-virus, anti-liver injury, anti-liver fibrosis, and liver cancer prevention, and a relatively high level of clinical evidence based medicine evidences are obtained.

A method for estimating portal blood flow and hepatic function in a subject is provided. In one example, the STAT test is an in vitro simplified, convenient test intended for screening purposes that can reasonably estimate the portal blood flow from a single blood sample taken 60 minutes after orally administered deuterated-cholate. The test can be administered to a patient having, or suspected of having, Chronic Hepatitis C, Primary Sclerosing Cholangitis (PSC), Non-Alcoholic Fatty Liver Disease (NAFLD), or any chronic liver disease.

The invention discloses a pharmaceutical composition for treating or preventing acute and chronic hepatic disease, which is prepared from Chinese medicinal herbs including Bupleurum root, licorice root, root of red rooted saliva, notoginseng, schisandra fruit, curcuma longa, picrorhiza rhizome, cow-bezoar, Chinese angelica root, herba patriniae, astragalus root and alisol. The invention also provides the method for preparation and use of the pharmaceutical composition.

The invention relates to a compound medicament for treating a chronic liver disease and a preparation method thereof. The compound medicament is prepared from artemisia capillaries, artemisia rupestris, cichorium glandulosum boiss et huet, rose, rhubarb and licorice which are used as raw materials and medicinal accessories and prepared into an oral preparation, syrup granules, hard capsules and tablets by adopting a method of solvent extraction, impurity removal, concentration and drying. The active ingredients in the compound medicament are dissolved by adopting a reasonable extraction method according to the Uyghur medicinal theory, the characteristics of national medicine and the long-term folk clinical practice of the Uyghur nationality, so that the medicinal effects are enhanced, and the bioavailability is improved. Animal experiments prove that the compound medicament has a protective effect on liver injury. Pharmacodynamic experiments show that the extract obtained by the method can inordinately reduce the alanine transaminase (ALT) and aspartate transferase (AST) levels in mouse serum of a liver injury model, the pathological symptoms in each medication administration team are relieved, and the liver injury is protected. Acute toxicity experiments show that the maximum dosage of the extract obtained by the method is equivalent to 337 folds of clinical human proposed dosage according to mouse intragastric single-time administration toxicity test, and the extract is nontoxic and safe.

The invention relates to a medicine composition for treating chronic liver disease and application thereof. The medicine composition is prepared from the following raw materials in parts by weight: 20-60 parts of kiwi-fruit juice, 10-30 parts of radix salviae miltiorrhizae, 5-15 parts of rhizoma atractylodis macrocephalae, 4-12 parts of herba epimedii, 4-12 parts of poria cocos, 2-6 parts of radix bupleuri, 5-15 parts of fructus schisandrae chinensis, 1.5-4.5 parts of cardamon fruit, 2.5-7.5 parts of tangerine peel and 5-15 parts of radix pseudostellariae. The medicine composition has the advantages that the application of the medicine composition can serve as a basic therapeutic method for regulating deficiency, nourishing yin and detoxifying and can integrate methods of clearing heat and removing toxicity, regulating qi and activating blood, strengthening spleen and harmonizing stomach, nourishing liver and kidney and the like by starting from spleen and kidney; the medicine compatibility according to the prescription strictly conforms to the traditional theory of traditional Chinese medicine and also refers to the optimal configuration of empirical and classical prescriptions, and the formula is strict and novel; the results of clinical and experimental studies prove that the medicine composition provided by the invention has an exact therapeutic effect on the chronic liver disease, is relatively low in cost, has no toxic and side effect, achieves a short course of treatment, a quick effect and a high curate rate, and ensures that the chronic liver disease basically does not relapse after being cured.

The invention relates to an inhibitor containing fused ring derivative as well as a preparation method and application thereof. Particularly, the invention relates to a compound as shown in a generalformula (I), a preparation method thereof, a pharmaceutical composition containing the compound, and application of the compound as a kinase inhibitor, particularly as a receptor tyrosine kinase inhibitor (TKI), more particularly as an EGFR (epidermal growth factor receptor) or HER2 (human epidermal growth factor receptor 2) inhibitor to treatment of cancer, inflammation, chronic liver diseases, diabetes, cardiovascular diseases, AIDS and other related diseases. Each substituent in the general formula (I) is the same as the definition in the specification.

The embodiments herein relate to the combination of herbal and probiotic (optionally with prebiotic) treatment for chronic liver diseases to be novel and more effective. Embodiments herein relate to a composition comprising a probiotic and a medicinal herb (and optionally a prebiotic), wherein the composition is effective in treating a liver disease such as inflammation of liver in a novel approach to disease management. The combination of a prebiotic, a probiotic and a medicinal herb constitutes a symbiotic formulation. Clinical and animal data exists to show efficacy of these combinations. The ingredients, as well as the categories, in the combination are novel. Using a combination of twelve herbs and three probiotics, a highly efficacious and novel supplement is disclosed herein. Embodiments of the compositions herein could further include homeopathic drugs and an active pharmaceutical ingredient such as an allopathic drug.

The invention provides a DCP quick separation detection kit, by which content of abnormal prothrombin (DCP) in a human serum sample can be quickly, accurately and quantitatively metered in vitro, so that the kit is mainly used in clinical identification and diagnosis on primary hepatocellular carcinoma (HCC), chronic liver diseases and benign hepatic space-occupying lesions.